Basilea Pharmaceutica AG
SIX:BSLN
Basilea Pharmaceutica AG
Basilea Pharmaceutica AG engages in the development and commercialization of pharmaceutical products. The company is headquartered in Basel, Basel-Stadt and currently employs 154 full-time employees. The company went IPO on 2004-03-25. The firm operates in one segment, which is the discovery, development and commercialization of innovative pharmaceutical products to meet the needs of patients with cancer and infectious diseases. The company launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. Additionally It is conducting clinical studies with two targeted drug candidates for the treatment of a range of cancers and have a number of preclinical assets in both cancer and infectious diseases in its portfolio.
Basilea Pharmaceutica AG engages in the development and commercialization of pharmaceutical products. The company is headquartered in Basel, Basel-Stadt and currently employs 154 full-time employees. The company went IPO on 2004-03-25. The firm operates in one segment, which is the discovery, development and commercialization of innovative pharmaceutical products to meet the needs of patients with cancer and infectious diseases. The company launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. Additionally It is conducting clinical studies with two targeted drug candidates for the treatment of a range of cancers and have a number of preclinical assets in both cancer and infectious diseases in its portfolio.
Cresemba Growth: Cresemba achieved about 25% year-on-year in-market sales growth and a 21.7% increase in royalty income, helping drive strong financial results.
Zevtera U.S. Launch: Zevtera was successfully launched in the U.S. through a partnership with Innoviva Specialty Therapeutics, expanding access to a major commercial market.
Strong Financial Performance: Operating profit rose to CHF 24 million for H1 2025, with total revenue up 36% to CHF 104 million and a shift from net debt to a positive net cash position.
Pipeline Expansion: The company in-licensed ceftibuten-ledaborbactam, an oral antibiotic set to enter Phase III in about 18 months, and advanced two Phase III trials for antifungal fosmanogepix.
Guidance Raised: 2025 total revenue guidance increased to CHF 225 million (was CHF 220 million), with operating profit expected at CHF 50 million and R&D expenses rising due to the new in-licensing deal.
Continued R&D Funding: Secured an additional USD 39 million in nondilutive BARDA funding to support clinical development efforts.
